Medivir AB (STO:MVIRB) will release the third quarter earnings for 2009 on Wednesday, October 21. The financial results will be posted on the company’s website at www.medivir.se/v3/en/ir_media/financial_reports.cfm.
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Stock Newsletter
Medivir AB is a Sweden-based pharmaceutical company that develops drugs against widespread diseases, with proteases as its target enzyme. It specializes in developing selective inhibitors that regulate the function of proteases in various diseases. The Company is focused on 16 projects such as Lipsovir, TMC435, MIV-701, HIV PI, Renin Hepatitis, Valomaciclovir and others. Medivir develops pharmaceuticals against major, widespread diseases like HIV, Alzheimer's disease, Bone disorders, Shingles and the hepatitis C segment. The Company engages in a number of partnerships with established pharmaceutical companies and smaller biotechnology enterprises on clinical and preclinical projects. The group consists of the parent company Medivir AB and the subsidiaries Medivir HIV Franchise AB, Medivir Personal AB and Medivir (UK) Ltd. The Company’s main shareholders are Bo Oberg, Nils-Gunnar Johansson, Staffan Rasjo, DNB Nor Bank AB, Skandia, among others.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
